SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001564590-20-019685
Filing Date
2020-04-29
Accepted
2020-04-29 16:00:36
Documents
6
Period of Report
2020-06-24
Effectiveness Date
2020-04-29

Document Format Files

Seq Description Document Type Size
1 DEF 14A sbph-def14a_20200624.htm DEF 14A 902761
2 GRAPHIC g5mah01fstaa000004.jpg GRAPHIC 69610
3 GRAPHIC g5mah01fstaa000003.jpg GRAPHIC 1901
4 GRAPHIC g5mah01fstaa000002.jpg GRAPHIC 1565
5 GRAPHIC g5mah01fstaa000005.jpg GRAPHIC 63478
6 GRAPHIC g5mah01fstaa000001.jpg GRAPHIC 5838
  Complete submission text file 0001564590-20-019685.txt   1100670
Mailing Address 35 PARKWOOD DRIVE SUITE 210 HOPKINTON MA 01748
Business Address 35 PARKWOOD DRIVE SUITE 210 HOPKINTON MA 01748 508-473-5993 X119
Spring Bank Pharmaceuticals, Inc. (Filer) CIK: 0001566373 (see all company filings)

IRS No.: 522386345 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37718 | Film No.: 20830093
SIC: 2834 Pharmaceutical Preparations